Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies
Open Access

Drugs Showing Real-world Efficacy for Nocturia in Patients With Bladder Storage Symptoms

KAZUNA TSUBOUCHI, NAOTAKA GUNGE, WATARU MATSUOKA, TAIKI EMOTO, TAKESHI MIYAZAKI, KOSUKE TOMINAGA, YU OKABE, HIROSHI MATSUZAKI, SHINTARO ASO, MASAHIRO TACHIBANA, CHIZURU NAKAGAWA, AIKO FUJIKAWA, NOBUYUKI NAKAMURA, HIROFUMI MATSUOKA and NOBUHIRO HAGA
Anticancer Research January 2023, 43 (1) 455-461; DOI: https://doi.org/10.21873/anticanres.16182
KAZUNA TSUBOUCHI
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOTAKA GUNGE
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WATARU MATSUOKA
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAIKI EMOTO
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI MIYAZAKI
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOSUKE TOMINAGA
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YU OKABE
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI MATSUZAKI
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINTARO ASO
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAHIRO TACHIBANA
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIZURU NAKAGAWA
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AIKO FUJIKAWA
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOBUYUKI NAKAMURA
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROFUMI MATSUOKA
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOBUHIRO HAGA
Department of Urology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nhaga@fukuoka-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Nocturia is defined as the symptom that an individual has to disrupt their sleep at night, for one or several times, in order to void. Nocturia is a bothersome event that markedly reduces a patient’s quality of life. The aim of the study was to elucidate which drugs, prescribed to reduce nocturia, show real-world efficacy in patients with bladder storage symptoms. Patients and Methods: One hundred consecutive patients who visited the Fukuoka University Medical Center were evaluated between May and July 2022. Anticholinergic drugs, β3 adrenoceptor agonists, α1 blockers, desmopressin, and other medicines were prescribed for relieving nocturia. Desmopressin was used as second-line treatment of nocturia only in males with nocturnal polyuria. The association between each drug and actual decrease in nocturia was investigated using multivariate analysis. Results: The number of nocturia episodes was reduced in patients using anticholinergic drugs, β3 adrenoceptor agonists, and desmopressin (−1.4±0.9, −1.3±0.9, −2.0 ±0.8 episodes/night, respectively). Multivariate analysis for the entire cohort showed that anticholinergic drugs and β3 adrenoceptor agonists were associated with significantly decreased nocturia episodes (p=0.01 and p=0.04, respectively). In males, only desmopressin was associated with a significant decrease in nocturia (p=0.03), and combination therapy significantly decreased the number of nocturia episodes compared to monotherapy (p=0.001). Conclusion: In a real-world clinical setting, anticholinergic drugs and β3 adrenoceptor agonists were similarly effective in reducing nocturia. Administration of desmopressin combined with anticholinergic drugs and/or β3 adrenoceptor agonists is the most effective method for reducing nocturia in male patients with both storage symptoms and nocturnal polyuria.

Key Words:
  • Desmopressin
  • nocturia
  • LUTS
  • β3 adrenoceptor agonist

Nocturia is defined as the symptom that an individual has to disrupt its sleep at night, for one or several times, in order to void. Nocturia is a bothersome event that markedly reduces the patient’s quality of life (1). Nocturia has been observed in 48.6% of male patients and 54.5% of female patients with lower urinary tract symptoms (LUTS) (2). In addition, nocturia has been associated with an increased risk of bone fractures and increased mortality rate (3). Nocturia is, thus, considered an urgent matter to be resolved by physicians. Although behavioral therapy is reportedly effective against nocturia (4), nocturia associated with bladder storage symptoms due to benign prostatic hyperplasia (BPH) and/or overactive bladder (OAB) was initially treated by pharmacotherapy in daily medical practice. In fact, α1 blockers, antimuscarinic drugs, β3 adrenoceptor agonists, among other drugs have been reported as effective not only for bladder storage symptoms, but also for nocturia (5-7). However, little real-world evidence exists on drugs prescribed for improving bladder storage symptoms and relieving nocturia in patients with bladder storage symptoms.

Oral desmopressin has been used for nocturia related to nocturnal polyuria in adults. The efficacy of desmopressin has been demonstrated in several studies (8, 9). Combination therapy using desmopressin with tolterodine also demonstrated additional improvement of nocturia compared to desmopressin alone (10). In existing research evaluating the efficacy of drugs used against LUTS, the included participants were patients with no comorbidities other than LUTS (11). In addition, a washout period was generally provided for any other drugs that could potentially relieve LUTS (12). However, in daily clinical practice, drugs relieving LUTS are administered to patients with several comorbidities without a washout period.

The aim of the present study was to elucidate which drugs related to improvement of nocturia show real-world efficacy against nocturia in patients with bladder storage symptoms in daily clinical practice.

Patients and Methods

Patients. The clinical cohort of this observational study included 100 consecutive patients with bladder storage symptoms and nocturia who visited a doctor regularly at the Fukuoka University Academic Hospital, Fukuoka, Japan. In this study, nocturia was considered present when there was a complaint by the individual of having to wake one or more times per night in order to void (13). All these patients had been diagnosed with BPH and/or OAB. BPH was diagnosed according to the clinical guidelines of the Japanese Urological Association for BPH and clinical guidelines for male LUTS and BPH (14, 15). OAB was also diagnosed based on the International Continence Society definition (16, 17). All patients were receiving pharmacotherapy for both storage symptoms and nocturia. We suspended enrolment in this study at 100 patients because our Academic Hospital was introducing a new study of nocturia after the completion of this study.

Exclusion criteria. Patients with urinary tract infection, clean intermittent catheterization, or injection of onabotulinum toxin into the bladder for OAB were excluded from the study.

Evaluation frequency of nocturia. Nocturnal frequency was evaluated twice by the physician in the outpatient clinic, both before and after pharmacotherapy. Nocturnal frequency after medical treatment was assessed at the follow-up visit by the physicians between May and July 2022.

Treatment strategy for nocturia in patients with bladder storage symptom. Anticholinergic drugs, β3 adrenoceptor agonists, α1 blockers, desmopressin, and other medicines (e.g., herbal medicines) were selected for relieving nocturia. Desmopressin was used as a second-line treatment of nocturia only for males with nocturnal polyuria, defined as a nocturnal polyuria index >33% (8), as the Japanese insurance system does not cover the use of desmopressin for females. Medical treatment was started as monotherapy at clinically recommended doses. However, if the effect of therapy was insufficient, the drug was changed or a combination drug regimen was initiated according to the discretion of the physician. If adverse events were reported by the patient, switching to other drugs was applied. No wash-out period was set when drugs were changed.

When administration of medications was continued for more than 1 month, the drug was judged as possessing therapeutic effect against nocturnal frequency. When medications were continued for less than one month, the drug was not used for judgement. Informed consent was obtained from all participants before study enrolment, after providing an explanation of its objectives and methods employed. All study protocols were approved by the Ethics Committee at our Institution (IRB registration number: H21-09-003).

Primary and secondary outcomes. The primary outcome of the present study was to identify which drugs had real-world effectiveness in reducing nocturia in patients with bladder storage symptoms. We, therefore, investigated the association between each drug and decrease in number of nocturia episodes. The secondary outcome was the association between patient characteristics and change in number of nocturia episodes.

Statistical analysis. All values are presented as mean±standard deviation. A two-sided Mann-Whitney U-test was used to determine the significance of differences in numbers of nocturia episodes. Correlations between continuous variables were investigated by simple regression analysis using the square of Pearson’s correlation coefficient. Multivariate analyses were performed using multiple linear regression to identify the pharmacological agents associated with decreases in nocturnal frequency. Values of p<0.05 were considered significant. Analysis was performed using JMP version 11.0 software (SAS, Cary, NC, USA).

Results

Baseline characteristics and perioperative outcomes for the 100 patients (72 men, 28 women) are presented in Table I. Patient age was 74±10 years. Mean age was significantly higher in men (76±1.2 years) than women (71±1.9 years, p<0.04). BPH was present in 66 patients and 88 patients had OAB. In the male cohort, BPH was present in 91.7% (66 of 72 patients), OAB in 83.3% (60 of 72 patients), and both BPH and OAB in 73% (57 of 72 patients). On the other hand, all female patients showed OAB. The number of patients with hypertension, diabetes mellitus, and dyslipidemia was 49, 28, and 22, respectively.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient characteristics.

Anticholinergic drugs, β3 adrenoceptor agonists, α1 blockers, desmopressin, and other therapeutic drugs (e.g., herbal medicines) were used for 39, 41, 60, 4, and 9 patients, respectively. The types of anticholinergic drugs and β3 adrenoceptor agonists are shown in Figure 1. The mean number of nocturia episodes before and after medical therapy was 3.3±1.2 and 1.9±1, respectively (p<0.001). Timing of therapy evaluation was 3.0±2.3 months. However, no significant association between timing of therapy evaluation and number of therapeutic drugs was observed in the present cohort (p=0.41).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Types of anticholinergic drugs and β3 adrenoceptor agonists used in the cohort. (A) Types of anticholinergic drugs used in the cohort. (B) Types of β3 adrenoceptor agonists used in the cohort.

Association between therapeutic drugs and decrease in nocturia episodes. The number of nocturia episodes was significantly reduced in patients receiving anticholinergic drugs (−1.4±0.9 episodes per night) compared to those not receiving (−1.0±0.8 episodes per night) (p=0.02) (Figure 2). The number of nocturia episodes was also significantly reduced in patients receiving β3 adrenoceptor agonists (−1.3±0.9 episodes per night) compared to those not receiving (−1.0±0.9 episodes per night) (p=0.04) (Figure 2). The number of nocturia episodes was not significantly reduced in patients receiving α1 blockers (−1.1±0.9 episodes per night) compared to those not receiving (−1.2±0.9 episodes per night) (p=0.62) (Figure 2). The number of nocturia episodes was significantly reduced in patients receiving desmopressin (−2.0±0.8 episodes per night) compared to those not receiving (−0.9±0.8 episodes per night) (p=0.03) (Figure 2).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Association between therapeutic drugs and change in number of nocturia episodes. (A) Anticholinergic drugs. (B) β3 adrenoceptor agonists. (C) α1 blockers. (D) Desmopressin. *p<0.05.

To confirm the therapeutic drugs affecting nocturia episodes, multivariate regression analysis was performed to determine which therapeutic drugs were most strongly associated with a decrease in the number of nocturia episodes (Table II and Table III). In analyses of the entire cohort, anticholinergic drugs, β3 adrenoceptor agonists, α1 blockers, and other therapeutic drugs were selected as independent variables (Table II). Multivariate regression analysis showed that anticholinergic drugs and β3 adrenoceptor agonists correlated significantly with a decrease in the number of nocturia episodes (p=0.01 and p=0.04, respectively). In analyses limited to the male cohort, anticholinergic drugs, β3 adrenoceptor agonists, α1 blockers, and desmopressin were selected as independent variables (Table III). Multivariate regression analyses showed that only desmopressin correlated significantly with a decrease in nocturia episodes (p=0.03).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Multivariate analyses of various therapeutic drugs affecting improvement in nocturia.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Multivariate analyses of various therapeutic drugs producing improvement in nocturia.

Association of patient characteristics and changes in nocturia episodes. No significant difference in the number of nocturia episodes before therapy was evident between males (3.1±1.1 episodes per night) and females (3.6±1.4 episodes per night) (p=0.24). After introducing therapeutic drugs, the decrease in the number of nocturia episodes was significantly greater in females (−1.7±1.0 episodes per night) than in males (−1.1±1.0 episodes per night, p=0.02). In the present study, an increased number of comorbidities (i.e., hypertension, diabetes mellitus, and dyslipidemia) was not significantly associated with an increase in the number of nocturia episodes.

In this study, 56 patients received one therapeutic drug and 44 patients received ≥2 drugs. Taking ≥2 drugs was associated with a significantly decreased number of nocturia events (−1.5±0.8 episodes per night) compared to one drug (−0.9±0.9 episodes per night) (p=0.001). No significant association was seen between timing of therapy evaluation and decrease in nocturia events in the present cohort (r=0.05) (p=0.51).

Discussion

In the present study, we evaluated which drugs showed real-world effectiveness for decreasing nocturia in patients with bladder storage symptoms. In the entire cohort, antimuscarinic drugs and β3 adrenoceptor agonists were seen to be significantly more effective than other drugs. The average decrease in nocturia was around 1.5 events per night for both agents. Few studies have investigated the efficacy of antimuscarinic drugs and β3 adrenoceptor agonists in reducing nocturia for patients with bladder storage symptoms. Weiss et al.. demonstrated that the anticholinergic drug fesoterodine significantly reduced nocturia by approximately 1.1 episodes per night compared to controls in a randomized controlled trial (RCT) (18). In addition, Yoshida et al.., in another RCT demonstrated that the β3 adrenoceptor agonist vibegron reduced nocturia by about 0.6 episodes per night compared to controls. Although the reduction in frequency of nocturia was better for anticholinergic drugs in those studies, the relative merits with regard to decreasing nocturia of antimuscarinic drugs and β3 adrenoceptor agonists remained unclear in the present study.

In our male cohort, desmopressin significantly reduced nocturia compared to other drugs (i.e., antimuscarinic drugs, β3 adrenoceptor agonists, α1 blockers, etc.). The decrease in nocturia episodes roughly doubled with the addition of desmopressin. These data were consistent with findings from other RCTs (9). Thus, in real-world settings, desmopressin might be the most effective option for reducing nocturia in male patients with both bladder storage symptoms and nocturnal polyuria.

In the present study, combination therapy was seen to contribute significantly to a reduction in nocturia. Several studies have demonstrated that combination therapy comprising an anticholinergic drug with a β3 adrenoceptor agonist was effective against OAB symptoms (7, 19, 20). Thus, given our results and findings from other Institutions, combination therapy appears to be more effective than switching to another monotherapy when first-line efficacy is insufficient.

Regarding sex differences, nocturnal frequency was found to be significantly reduced in female patients than in male patients. This finding is consistent with other reports (21). The reason why greater efficacy was seen for female patients in reduction of nocturnal frequency has been suggested to involve a greater magnitude of a placebo effect in female patients than in male patients (8).

Kopelke et al.. demonstrated that pre-radiotherapy sleep disturbances occurred in prostate cancer patients receiving definitive or adjuvant radiotherapy (22). The risk factors for pre-radiotherapy sleep disturbances were significantly associated with a depressive tendency, as evaluated by a patient questionnaire (22). However, the authors did not show that the depressive tendency was induced by an increase in nocturnal void frequency. If depressive tendency was indeed associated with nocturia, the drugs used to improve the nocturnal frequency might also relieve the pre-radiotherapy sleep disturbances.

Several limitations must be considered when interpreting the results presented herein. First, because the present study was performed in a real-world clinical setting, the sequential order of drugs, types of drugs, administration of mono- or combination therapy, etc., depended on decisions made by the individual physician. Treatment strategies were, thus, inconsistent in the present study. These matters might affect the degree of decrease in nocturia episodes. Second, because patients in the present study were regularly visiting a doctor at a University Hospital, some degree of selection bias for patients was likely present. The patients might have had a greater number of comorbidities or severe lower urinary symptoms; therefore, the efficacy of drugs for nocturnal frequency might have had different effects on them. Third, the timing of drug efficacy evaluation was different for each patient. It is possible that longer assessment intervals could have induced an increase in the number of drugs taken orally. However, no significant association was found between longer intervals between evaluations and increase of the number of drugs, or between longer interval and decreased nocturnal frequency. Inconsistencies in the timing of evaluations might, thus, have had a minimal effect on the present results. Finally, in the present study, nocturnal frequency was not evaluated through frequency volume charts, but based on inquiries made during follow-up at the outpatient clinic. Some recall bias may therefore have occurred.

Conclusion

In a real-world clinical setting, anticholinergic drugs and β3 adrenoceptor agonists showed similar efficacy in reducing nocturia for patients with bladder storage symptoms. Desmopressin was the only treatment significantly associated with a reduction in nocturia for the male-only cohort. In addition, combination therapy was more effective than monotherapy in reducing nocturia. The addition of desmopressin after administration of an anticholinergic drug and/or β3 adrenoceptor agonist might, thus, represent the most effective option for reducing nocturia in male patients with both bladder storage symptoms and nocturnal polyuria.

Footnotes

  • Authors’ Contributions

    Kazuna Tsubouchi contributed to the conception and design of the study. Naotaka Gunge contributed to drafting the manuscript. Wataru Matsuoka contributed to drafting the manuscript. Taiki Emoto, Takeshi Miyazaki, Kosuke Tominaga, Yu Okabe, Hiroshi Matsuzaki, Shintaro Aso, and Masahiro Tachibana contributed to data acquisition. Chizuru Nakagawa contributed to analysis and interpretation of data. Aiko Fujikawa and Nobuyuki Nakamura contributed to analysis and interpretation of data. Hirofumi Matsuoka and Nobuhiro Haga supervised the study.

  • Conflicts of Interest

    The Authors declare no conflicts of Interest.

  • Received September 27, 2022.
  • Revision received October 13, 2022.
  • Accepted October 20, 2022.
  • Copyright © 2023 The Author(s). Published by the International Institute of Anticancer Research.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Tikkinen KA,
    2. Johnson TM 2nd.,
    3. Tammela TL,
    4. Sintonen H,
    5. Haukka J,
    6. Huhtala H and
    7. Auvinen A
    : Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol 57(3): 488-496, 2010. PMID: 19361907. DOI: 10.1016/j.eururo.2009.03.080
    OpenUrlCrossRefPubMed
  2. ↵
    1. Irwin DE,
    2. Milsom I,
    3. Hunskaar S,
    4. Reilly K,
    5. Kopp Z,
    6. Herschorn S,
    7. Coyne K,
    8. Kelleher C,
    9. Hampel C,
    10. Artibani W and
    11. Abrams P
    : Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6): 1306-14; discussion 1314-5, 2006. PMID: 17049716. DOI: 10.1016/j.eururo.2006.09.019
    OpenUrlCrossRefPubMed
  3. ↵
    1. Nakagawa H,
    2. Niu K,
    3. Hozawa A,
    4. Ikeda Y,
    5. Kaiho Y,
    6. Ohmori-Matsuda K,
    7. Nakaya N,
    8. Kuriyama S,
    9. Ebihara S,
    10. Nagatomi R,
    11. Tsuji I and
    12. Arai Y
    : Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol 184(4): 1413-1418, 2010. PMID: 20727545. DOI: 10.1016/j.juro.2010.05.093
    OpenUrlCrossRefPubMed
  4. ↵
    1. Cornu JN,
    2. Abrams P,
    3. Chapple CR,
    4. Dmochowski RR,
    5. Lemack GE,
    6. Michel MC,
    7. Tubaro A and
    8. Madersbacher S
    : A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management – a systematic review and meta-analysis. Eur Urol 62(5): 877-890, 2012. PMID: 22840350. DOI: 10.1016/j.eururo.2012.07.004
    OpenUrlCrossRefPubMed
  5. ↵
    1. Lee CL and
    2. Kuo HC
    : Male patients with a higher frequency of nocturnal urinary episodes are more likely to benefit from alpha-blocker therapy for bothersome nocturia. Low Urin Tract Symptoms 11(2): O174-O179, 2019. PMID: 30548822. DOI: 10.1111/luts.12246
    OpenUrlCrossRefPubMed
    1. Yokoyama O,
    2. Yamaguchi O,
    3. Kakizaki H,
    4. Itoh N,
    5. Yokota T,
    6. Okada H,
    7. Ishizuka O,
    8. Ozono S,
    9. Gotoh M,
    10. Sugiyama T,
    11. Seki N,
    12. Yoshida M and
    13. Yamada S
    : Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J Urol 186(1): 170-174, 2011. PMID: 21575976. DOI: 10.1016/j.juro.2011.02.2700
    OpenUrlCrossRefPubMed
  6. ↵
    1. Yamaguchi O,
    2. Kakizaki H,
    3. Homma Y,
    4. Igawa Y,
    5. Takeda M,
    6. Nishizawa O,
    7. Gotoh M,
    8. Yoshida M,
    9. Yokoyama O,
    10. Seki N,
    11. Okitsu A,
    12. Hamada T,
    13. Kobayashi A and
    14. Kuroishi K
    : Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int 116(4): 612-622, 2015. PMID: 25639296. DOI: 10.1111/bju.13068
    OpenUrlCrossRefPubMed
  7. ↵
    1. Yamaguchi O,
    2. Juul KV,
    3. Falahati A,
    4. Yoshimura T,
    5. Imura F and
    6. Kitamura M
    : Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program. Low Urin Tract Symptoms 12(1): 8-19, 2020. PMID: 31397969. DOI: 10.1111/luts.12276
    OpenUrlCrossRefPubMed
  8. ↵
    1. Juul KV,
    2. Klein BM and
    3. Nørgaard JP
    : Long-term durability of the response to desmopressin in female and male nocturia patients. Neurourol Urodyn 32(4): 363-370, 2013. PMID: 22972524. DOI: 10.1002/nau.22306
    OpenUrlCrossRefPubMed
  9. ↵
    1. Rovner ES,
    2. Raymond K,
    3. Andruczyk E and
    4. Juul KV
    : Low-dose desmopressin and tolterodine combination therapy for treating nocturia in women with overactive bladder: a double-blind, randomized, controlled study. Low Urin Tract Symptoms 10(3): 221-230, 2018. PMID: 28560762. DOI: 10.1111/luts.12169
    OpenUrlCrossRefPubMed
  10. ↵
    1. Rackley R,
    2. Weiss JP,
    3. Rovner ES,
    4. Wang JT,
    5. Guan Z and 037 STUDY GROUP
    : Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 67(4): 731-6; discussion 736, 2006. PMID: 16618562. DOI: 10.1016/j.urology.2005.10.061
    OpenUrlCrossRefPubMed
  11. ↵
    1. Robinson D,
    2. Kelleher C,
    3. Staskin D,
    4. Mueller ER,
    5. Falconer C,
    6. Wang J,
    7. Ridder A,
    8. Stoelzel M,
    9. Paireddy A,
    10. van Maanen R,
    11. Hakimi Z and
    12. Herschorn S
    : Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourol Urodyn 37(1): 394-406, 2018. PMID: 28704584. DOI: 10.1002/nau.23315
    OpenUrlCrossRefPubMed
  12. ↵
    1. Hashim H,
    2. Blanker MH,
    3. Drake MJ,
    4. Djurhuus JC,
    5. Meijlink J,
    6. Morris V,
    7. Petros P,
    8. Wen JG and
    9. Wein A
    : International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract function. Neurourol Urodyn 38(2): 499-508, 2019. PMID: 30644584. DOI: 10.1002/nau.23917
    OpenUrlCrossRefPubMed
  13. ↵
    1. Homma Y,
    2. Gotoh M,
    3. Yokoyama O,
    4. Masumori N,
    5. Kawauchi A,
    6. Yamanishi T,
    7. Ishizuka O,
    8. Seki N,
    9. Kamoto T,
    10. Nagai A,
    11. Ozono S and Japanese Urological Association
    : Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol 18(11): 741-756, 2011. PMID: 22050351. DOI: 10.1111/j.1442-2042.2011.02860.x
    OpenUrlCrossRefPubMed
  14. ↵
    1. Homma Y,
    2. Gotoh M,
    3. Kawauchi A,
    4. Kojima Y,
    5. Masumori N,
    6. Nagai A,
    7. Saitoh T,
    8. Sakai H,
    9. Takahashi S,
    10. Ukimura O,
    11. Yamanishi T,
    12. Yokoyama O,
    13. Yoshida M and
    14. Maeda K
    : Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol 24(10): 716-729, 2017. PMID: 28748576. DOI: 10.1111/iju.13401
    OpenUrlCrossRefPubMed
  15. ↵
    1. Abrams P,
    2. Cardozo L,
    3. Fall M,
    4. Griffiths D,
    5. Rosier P,
    6. Ulmsten U,
    7. van Kerrebroeck P,
    8. Victor A and
    9. Wein A
    : The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 187(1): 116-126, 2002. PMID: 12114899. DOI: 10.1067/mob.2002.125704
    OpenUrlCrossRefPubMed
  16. ↵
    1. Wein AJ and
    2. Rovner ES
    : Definition and epidemiology of overactive bladder. Urology 60(5 Suppl 1): 7-12; discussion 12, 2002. PMID: 12493342. DOI: 10.1016/s0090-4295(02)01784-3
    OpenUrlCrossRefPubMed
  17. ↵
    1. Weiss JP,
    2. Jumadilova Z,
    3. Johnson TM 2nd.,
    4. Fitzgerald MP,
    5. Carlsson M,
    6. Martire DL and
    7. Malhotra A
    : Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. J Urol 189(4): 1396-1401, 2013. PMID: 23159276. DOI: 10.1016/j.juro.2012.11.067
    OpenUrlCrossRefPubMed
  18. ↵
    1. Abrams P,
    2. Kelleher C,
    3. Staskin D,
    4. Kay R,
    5. Martan A,
    6. Mincik I,
    7. Newgreen D,
    8. Ridder A,
    9. Paireddy A and
    10. van Maanen R
    : Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol 35(5): 827-838, 2017. PMID: 27514371. DOI: 10.1007/s00345-016-1908-1
    OpenUrlCrossRefPubMed
  19. ↵
    1. Herschorn S,
    2. Chapple CR,
    3. Abrams P,
    4. Arlandis S,
    5. Mitcheson D,
    6. Lee KS,
    7. Ridder A,
    8. Stoelzel M,
    9. Paireddy A,
    10. van Maanen R and
    11. Robinson D
    : Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 120(4): 562-575, 2017. PMID: 28418102. DOI: 10.1111/bju.13882
    OpenUrlCrossRefPubMed
  20. ↵
    1. Yamaguchi O,
    2. Nishizawa O,
    3. Juul KV and
    4. Nørgaard JP
    : Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial. BJU Int 111(3): 474-484, 2013. PMID: 23046147. DOI: 10.1111/j.1464-410X.2012.11547.x
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 43 (1)
Anticancer Research
Vol. 43, Issue 1
January 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Drugs Showing Real-world Efficacy for Nocturia in Patients With Bladder Storage Symptoms
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
13 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Drugs Showing Real-world Efficacy for Nocturia in Patients With Bladder Storage Symptoms
KAZUNA TSUBOUCHI, NAOTAKA GUNGE, WATARU MATSUOKA, TAIKI EMOTO, TAKESHI MIYAZAKI, KOSUKE TOMINAGA, YU OKABE, HIROSHI MATSUZAKI, SHINTARO ASO, MASAHIRO TACHIBANA, CHIZURU NAKAGAWA, AIKO FUJIKAWA, NOBUYUKI NAKAMURA, HIROFUMI MATSUOKA, NOBUHIRO HAGA
Anticancer Research Jan 2023, 43 (1) 455-461; DOI: 10.21873/anticanres.16182

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Drugs Showing Real-world Efficacy for Nocturia in Patients With Bladder Storage Symptoms
KAZUNA TSUBOUCHI, NAOTAKA GUNGE, WATARU MATSUOKA, TAIKI EMOTO, TAKESHI MIYAZAKI, KOSUKE TOMINAGA, YU OKABE, HIROSHI MATSUZAKI, SHINTARO ASO, MASAHIRO TACHIBANA, CHIZURU NAKAGAWA, AIKO FUJIKAWA, NOBUYUKI NAKAMURA, HIROFUMI MATSUOKA, NOBUHIRO HAGA
Anticancer Research Jan 2023, 43 (1) 455-461; DOI: 10.21873/anticanres.16182
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer
  • Google Scholar

More in this TOC Section

  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
Show more Clinical Studies

Similar Articles

Keywords

  • desmopressin
  • nocturia
  • LUTS
  • β3 adrenoceptor agonist
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire